Cargando…
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
BACKGROUND: Visceral leishmaniasis (VL) is a protozoan disease that is invariably fatal if left untreated. The disease is found in 70 countries with incidence of 0.2 – 0.4 million cases. The mainstay of treatment in resource limited countries like Ethiopia is antimonials, while use of liposomal amph...
Autores principales: | Tamiru, Aschalew, Tigabu, Bethlehem, Yifru, Sisay, Diro, Ermias, Hailu, Asrat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057416/ https://www.ncbi.nlm.nih.gov/pubmed/27724891 http://dx.doi.org/10.1186/s12879-016-1746-1 |
Ejemplares similares
-
Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011) -
Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014) -
High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2014) -
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018) -
Acute kidney injury in patients with Visceral Leishmaniasis in Northwest Ethiopia
por: Hailu, Workagegnehu, et al.
Publicado: (2021)